JPJi Young Park

Ji Young Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ji Young Park has a total of 146 co-authors. Here are the top co-authors by number of shared publications:

  • Seung Hun Jang

    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea

    10 shared publications
  • Yong Il Hwang

    Hallym Univ, Sacred Heart Hosp, Coll Med, Div Pulm Allergy & Crit Med,Dept Internal Med, Anyang, South Korea

    9 shared publications
  • Ki-Suck Jung

    Hallym Univ, Sacred Heart Hosp, Coll Med, Div Pulm Allergy & Crit Med,Dept Internal Med, Anyang, South Korea

    8 shared publications
  • Seung Hun Jang

    Hallym Univ, Sacred Heart Hosp, Coll Med, Div Pulm Allergy & Crit Med,Dept Internal Med, Anyang, South Korea

    8 shared publications
  • Sunghoon Park

    Hallym Univ, Sacred Heart Hosp, Coll Med, Div Pulm Allergy & Crit Med,Dept Internal Med, Anyang, South Korea

    8 shared publications
  • Sunghoon Park

    Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea

    8 shared publications

Latest Publications

  • Open Access

    Advances and challenges in circulating tumor DNA-based early detection of lung cancer

    by Jung-Ki Yoon, Ji Young Park, Yeon Wook Kim, Hyung-Joo Oh, Young-Chul Kim

    Lung cancer remains the leading cause of cancer-related mortality worldwide. The primary reason for this poor prognosis is late-stage diagnosis, as approximately 50% of lung cancer cases are detected at stage 4 when curative treatment is no longer an option, and the 5-year survival of this stage is approximately 15%. While low-dose computed tomography (LDCT) has significantly improved early detection, its high false-positive rate (60–70%) leads to unnecessary invasive procedures and patient anxiety. Therefore, a complementary, highly specific, and non-invasive biomarker is urgently needed. Liquid biopsy, particularly circulating tumor DNA (ctDNA) analysis, has emerged as a promising diagnostic tool for lung cancer screening. Unlike conventional tissue biopsies, ctDNA-based tests provide a minimally invasive means to detect cancer-specific genomic alterations, including somatic mutations, DNA methylation patterns, somatic copy number alterations (CNAs), and fragment size variations. While ctDNA analysis has demonstrated clinical utility in advanced lung cancer, its application in early-stage disease remains challenging due to the low abundance of ctDNA in circulation. Strategies such as whole-genome methylation profiling, CNA analysis, and fragmentomics have been explored to enhance sensitivity and specificity for early detection. This review summarizes recent advances and challenges in ctDNA-based lung cancer screening, focusing on the strengths and limitations of different approaches. We highlight the need for integrating ctDNA assays with current LDCT screening protocols to improve diagnostic accuracy. Future large-scale prospective studies are essential to validate the clinical utility of ctDNA-based liquid biopsy in early lung cancer detection. A multi-modal biomarker strategy that combines genetic, epigenetic, and structural features holds great promise for transforming lung cancer screening and improving clinical outcomes.


  • Incidence, risk factors, and final causes for misdiagnosis of tuberculosis in the Republic of Korea: a population-based longitudinal analysis

    by Changwhan Kim, Yousang Ko, Jin-Wook Moon, Yong-Bum Park, So Young Park, Ga-Young Ban, Ju Yeun Song, Hajeong Kim, Yun Su Sim, Ji Young Park, et al.


  • Open Access

    Clinical characteristics of patients with COVID-19 vaccine-related pneumonitis: a case series and literature review

    by Ji Young Park, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Hwan Il Kim, Seung Hun Jang, Ki-Suck Jung, Yong Kyun Kim, Hyun Ah Kim, In Jae Lee

    Background/Aims: Pulmonary toxicities of coronavirus disease 2019 (COVID-19) vaccination are exceedingly rare. However, there are a few reported cases after mRNA vaccination, especially from Asian countries. The purpose of this study was to report the clinical characteristics of patients with COVID-19 vaccine-related pneumonitis (CV-P) and to review cases reported in the literature.Methods: We performed a prospective, observational case series analysis.Results: Eleven patients with a median age of 80 years were enrolled. Ten patients developed CV-P after BNT162b2-mRNA vaccination and one after ChAdOx1 nCoV-19 vaccination. We identified various patterns of CV-P, including transient infiltration, life-threatening acute respiratory distress syndrome, and aggravation of underlying interstitial lung disease. Most patients showed favorable outcomes with good responses to corticosteroid therapy.Conclusions: Identifying the mechanism of CV-P requires further investigation; however, radiological and laboratory findings in our case series support inflammatory dysregulation in the lung parenchyma after vaccination. Clinicians should consider CV-P in patients with atypical lung infiltration, no specific etiologies, and recent COVID-19 vaccination


  • Open Access

    Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib

    by Ji Young Park, Seung Hun Jang, Chang Youl Lee, Taehee Kim, Soo Jie Chung, Ye Jin Lee, Hwan Il Kim, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, et al.

    Background: The remarkable efficacy of osimertinib in non‒small cell lung cancer (NSCLC) with acquired T790M mutation has been widely documented in clinical trials and real-world practice. However, some patients show primary resistance to this drug. Even patients who initially show a favorable response have inconsistent clinical outcomes later. Therefore, the aim of this study was to identify additional clinical predictive factors for osimertinib efficacy.Methods: A prospective cohort of patients with acquired T790M positive stage IV lung adenocarcinoma treated with osimertinib salvage therapy in Hallym University Medical Center were analyzed.Results: Sixty-one eligible patients were analyzed, including 38 (62%) women and 39 (64%) who never smoked. Their mean age was 63.3 years. The median follow-up after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) was 36.0 months (interquartile range, 24.7–50.2 months). The majority (n=45, 74%) of patients were deceased. Based on univariate analysis, low baseline neutrophil-to-lymphocyte ratios (NLR), age ≥50 years, never-smoking history, stage IVA at osimertinib initiation, and prolonged response to previous TKIs (≥10 months) were associated with a significantly longer progression-free survival (PFS). Multivariate analysis showed that never-smoking status (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.30–0.98; p=0.041) and a baseline NLR less than or equal to 3.5 (HR, 0.23; 95% CI, 0.12–0.45; p<0.001) were independently associated with a prolonged PFS with osimertinib.Conclusion: Smoking history and high NLR were independent negative predictors of osimertinib PFS in patients with advanced NSCLC developing EGFR T790M resistance after the initial EGFR-TKI treatment.


  • Open Access

    Changes in respiratory virus infection trends during the COVID-19 pandemic in South Korea: the effectiveness of public health measures

    by Ji Young Park, Hwan Il Kim, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Seung Hun Jang, Yong Kyun Kim, Ki-Suck Jung

    Background/Aims: Studies on the effectiveness of public health measures to prevent respiratory virus transmission in real-world settings are lacking. We investigated the effectiveness of universal mask use and adherence to other personal preventive measures on the changing viral respiratory infection patterns during the coronavirus disease 2019 (COVID-19) pandemic.Methods: Data were extracted from the South Korean National Respiratory Virus Sentinel Surveillance System. During the COVID-19 pandemic, a cross-sectional survey on adherence to personal preventive measures was conducted. Additionally, the number of subway passengers was analyzed to estimate physical distancing compliance.Results: During the pandemic, adherence to personal preventive measures significantly increased, particularly indoors and on public transportation. Respiratory virus trends were compared based on laboratory surveillance data of 47,675 patients with acute respiratory infections (2016 to 2020). The 2019 to 2020 influenza epidemic ended within 3 weeks, from the epidemic peak to the epidemic end, quickly ending the inf luenza season; with a 1.8- to 2.5-fold faster decline than in previous seasons. Previously, the overall respiratory virus positivity rate remained high after the influenza seasons had ended (47.7% to 69.9%). During the COVID-19 pandemic, this positive rate, 26.5%, was significantly lower than those in previous years. Hospital-based surveillance showed a decreased number of hospitalized patients with acute viral respiratory illnesses.Conclusions: This study suggests that high compliance to the use of personal preventive measures in public might reduce the incidence of all respiratory virus infections and its hospitalization rates, with no additional quarantine, isolation, or contact screening.


  • Open Access

    COVID-19 vaccine-related interstitial lung disease: a case study

    by Ji Young Park, Joo-Hee Kim, In Jae Lee, Hwan Il Kim, Sunghoon Park, Yong Il Hwang, Seung Hun Jang, Ki-Suck Jung

    Herd immunity through extensive and rapid vaccination rather than natural immunity acquired by infection is necessary to control a global pandemic like COVID-19. The development of COVID-19 vaccines has been accelerated through government funding and the collaborative efforts of the medical–scientific institutions and the pharmaceutical industry.1 2 In South Korea, the ChAdOx1 nCoV-19 (Oxford/AstraZeneca) and BNT162b2 (Pfizer/BioNTech) vaccines have received emergency approval and are being used. Although the safety and efficacy of these vaccines were established through interim analysis in global clinical trials, long-term data and reports of rare adverse reactions remain inadequate.1 2 We report a case of interstitial lung disease (ILD) after COVID-19 vaccination and review the literature on influenza vaccine-related ILDs. This review is favourable as influenza vaccines are widely administered annually among the elderly, and several vaccine-related ILDs have been reported.


  • Open Access

    Respiratory virus surveillance in Canada during the COVID-19 pandemic: An epidemiological analysis of the effectiveness of pandemic-related public health measures in reducing seasonal respiratory viruses test positivity

    by Kyu Young Park, Sumin Seo, Junhee Han, Ji Young Park

    Background: Various public health measures have been implemented globally to counter the coronavirus disease 2019 (COVID-19) pandemic. The purpose of this study was to evaluate respiratory virus surveillance data to determine the effectiveness of such interventions in reducing transmission of seasonal respiratory viruses. Method: We retrospectively analysed data from the Respiratory Virus Detection Surveillance System in Canada, before and during the COVID-19 pandemic, by interrupted time series regression. Results: The national level of infection with seasonal respiratory viruses, which generally does not necessitate quarantine or contact screening, was greatly reduced after Canada imposed physical distancing and other quarantine measures. The 2019–2020 influenza season ended earlier than it did in the previous year. The influenza virus was replaced by rhinovirus/enterovirus or parainfluenza virus in the previous year, with the overall test positivity remaining at approximately 35%. However, during the 2019–2020 post-influenza period, the overall test positivity of respiratory viruses during the COVID-19 was still low (7.2%). Moreover, the 2020–2021 influenza season had not occurred by the end of February 2021. Conclusion: Respiratory virus surveillance data may provide real-world evidence of the effectiveness of implemented public health interventions during the current and future pandemics.


  • Open Access

    A local experience of non-operative management for an appendicitis cohort during COVID-19

    by Dinh Van Chi Mai, Alex Sagar, Nainika Suresh Menon, Oliver Claydon, Ji Young Park, Billy Down, Barrie David Keeler

    Background: During the first United Kingdom COVID-19 wave, the Royal Colleges of Surgeons initially recommended conservative management with antibiotics instead of surgery for appendicitis. This study compared local outcomes of appendicitis during this period with a pre-COVID-19 cohort. Methods: An observational study was conducted in a district general hospital. All episodes of appendicitis were prospectively studied from 25th March 2020 until 26th May 2020 and compared with a retrospective pre-COVID cohort from 27th November 2019 until 29th January 2020. Primary outcome was 30-day treatment failure of simple appendicitis for conservatively managed cases during COVID-19 compared to surgically managed cases pre-pandemic. Treatment failure was defined as any unplanned radiological or surgical intervention. Results: Over nine weeks, there were 39 cases of appendicitis during COVID-19 and 50 cases pre-COVID-19. Twenty-six and 50 cases underwent appendicectomy during and pre-COVID-19 respectively. There was no difference in 30-day postoperative complication rates and nor were there any peri-operative COVID-19 infections. Twelve cases of simple appendicitis underwent conservative management during COVID-19 and were compared with 23 operatively managed simple cases pre-pandemic. There was a higher failure rate in the conservative versus operative group (33.3 vs 0% OR = 24.88, 95% CI 1.21 to 512.9, p=0.0095). Length of stay was similar (1.5 vs 2.0 p=0.576). Discussion: Locally, conservative management was more likely to fail than initial appendicectomy. We suggest that surgery should remain first line for appendicitis, with conservative management reserved for those with suspected or proven COVID-19 infection.


  • Open Access

    Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis

    by Joo-Hee Kim, Ji Young Park, Seung Hun Jang, Jwa-Kyung Kim, Young Rim Song, Hyung Seok Lee, Sung Gyun Kim

    Kim JH, et al. Allergy Asthma Immunol Res. 2021 May;13(3):517-519. https://doi.org/10.4168/aair.2021.13.3.517


  • Open Access

    Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea

    by Ji Young Park, Ye Jin Lee, Taehee Kim, Chang Youl Lee, Hwan Il Kim, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Ki-Suck Jung, Seung Hun Jang

    Background: The COVID-19 pandemic is predicted to significantly affect patients with lung cancer, owing to its rapid progression and high mortality. Studies on lung cancer diagnosis and treatment during an epidemic are lacking. We analyzed the impact of COVID-19 on lung cancer diagnosis in Korea, where lung cancer incidence continues to rise. Methods: The number of newly diagnosed lung cancer cases in three university-affiliated hospitals during the pandemic and their clinical features were compared with lung cancer cases diagnosed during the same period in the past 3 years. The effectiveness of measures taken by the study hospitals to prevent nosocomial transmission was reviewed. Results: A total of 612 patients were diagnosed with lung cancer from February through June, 2017–2020. During the pandemic, the number of patients who sought consultation at the division of pulmonology of study hospitals dropped by 16% from the previous year. Responding to the pandemic, the involved hospitals created physically isolated triage areas for patients with acute respiratory infection symptoms. Wide-range screening and preventive measures were implemented, thus minimizing the delay in lung cancer diagnosis. No patient acquired COVID-19 due to hospital exposure. The proportion of patients with stage III–IV non-small-cell lung cancer (NSCLC) significantly increased (2020: 74.7% vs. 2017: 57.9%, 2018: 66.7%, 2019: 62.7%, p = 0.011). The number of lung cancers diagnosed during this period and the previous year remained the same. Conclusions: The proportion of patients with advanced NSCLC increased during the COVID-19 pandemic.